Abstract
Patient was a 65 years old female with BCR-ABL-positive chronic myelogenous leukemia (CML) on Dasatinib 70 mg twice daily, presented with gradually worsening shortness of breath. Chest X ray showed moderate to large size bilateral pleural effusion. Thoracentesis done and dose of Dasatinib reduced from 70 mg twice daily to 100 mg daily. Eventually dose of dasatinib reduced to 50 mg daily due to recurrent pleural effusions. Then after Dasatinib discontinued due to proteinuria. Patient was started on imatinib 400 mg daily.
Imatinib was also put on hold due to grade 3 heart failure, periorbital edema, increased shortness of breath and nonproductive cough.
Pleural effusion size reduced. Finally, she was started on bosutinib 400 mg three times per day. Two months later, she again presented with large left side pleural effusion. Thoracentesis performed. Dose of bosutinib reduced to 400 mg daily. On further follow up, there was no recurrence of pleural effusion.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Goldblatt M, Huggins JT, Doelken P, Gurung P, Sahn SA. Dasatinib-induced pleural effusions: a lymphatic network disorder? Am J Med Sci. 2009;338:414–7.
Huang YM, Wang CH, Huang JS, Yeh KY, Lai CH, Wu TH, et al. Dasatinib-related chylothorax. Turk J Haematol. 2015;32:68–72.
aydas S. Dasatinib, large granular lymphocytosis, and pleural effusion: useful or adverse effect? Crit Rev Oncol Hematol. 2014;89:242–7.
Montani D, Bergot E, Günther S, et al. Pulmonary arterial hypertension in patients treated by dasatinib. Circulation. 2012;125(17):2128–37.
Moguillansky NI, Fakih HAM, Wingard JR. Bosutinib induced pleural effusions: Case report and review of tyrosine kinase inhibitors induced pulmonary toxicity. Respir Med Case Rep. 2017;21:154–7. https://doi.org/10.1016/j.rmcr.2017.05.003. PMID: 28560147; PMCID: PMC5435591
2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS) Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT).
Orlandi EM, Rocca B, Pazzano AS, Ghio S. Reversible pulmonary arterial hypertension likely related to long-term, low dose dasatinib treatment for chronic myeloid leukaemia. Leuk Res. 2012;36(1):e4–6.
Cortes JE, Saglio G, Kantarjian HM, et al. Final 5-year study results of DASISION: the dasatinib versus imatinib study in treatment-naïve chronic myeloid leukemia patients trial. J Clin Oncol. 2016;34(20):2333–40.
Caldemeyer L, Dugan M, Edwards J, Akard L. Long-term side effects of tyrosine kinase inhibitors in chronic myeloid leukemia. Curr Hematol Malign Rep. 2016;11(2):71–9.
Sleijfer S. Bleomycin-induced pneumonitis. Chest. 2001;120(2):617–24. https://doi.org/10.1378/chest.120.2.617. PMID: 11502668.
O’Sullivan JM, Huddart RA, Norman AR, Nicholls J, Dearnaley DP, Horwich A. Predicting the risk of bleomycin lung toxicity in patients with germ-cell tumours. Ann Oncol. 2003;14(1):91–6. https://doi.org/10.1093/annonc/mdg020. PMID: 12488299.
Jacobs C, Slade M, Lavery B. Doxorubicin and BOOP. A possible near fatal association. Clin Oncol (R Coll Radiol). 2002;14(3):262. https://doi.org/10.1053/clon.2002.0071. PMID: 12109837.
Miyakoshi S, Kami M, Yuji K, Matsumura T, Takatoku M, Sasaki M, Narimatsu H, Fujii T, Kawabata M, Taniguchi S, Ozawa K, Oshimi K. Severe pulmonary complications in Japanese patients after bortezomib treatment for refractory multiple myeloma. Blood. 2006;107(9):3492–4. https://doi.org/10.1182/blood-2005-11-4541. Epub 2006 Jan 12. PMID: 16410442.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Copyright information
© 2021 The Author(s), under exclusive license to Springer Nature Switzerland AG
About this chapter
Cite this chapter
Rohani, A. (2021). Dasatinib Induced Pleural Effusion and Pulmonary Hypertension. In: Clinical Cases in Cardio-Oncology. Clinical Cases in Cardiology. Springer, Cham. https://doi.org/10.1007/978-3-030-71155-9_2
Download citation
DOI: https://doi.org/10.1007/978-3-030-71155-9_2
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-71154-2
Online ISBN: 978-3-030-71155-9
eBook Packages: MedicineMedicine (R0)